Tysabri 300 mg

Tysabri (Natalizumab) is a biologic monoclonal antibody medication approved for the treatment of certain autoimmune conditions when other therapies have failed.

 Indications:

• Relapsing‑remitting multiple sclerosis (MS) and active secondary progressive MS after failure of other treatments

• Moderately to severely active Crohn’s disease in adults not responding to standard therapies

 Key Benefits:

• Reduces immune-mediated inflammation in the central nervous system or gastrointestinal tract

• Effective option for complex and severe immune-driven disease when other medications are inadequate

Administration:

• Delivered as an intravenous infusion (IV) in a clinical setting

• Typical dose: 300 mg every 4 weeks for MS or Crohn’s disease

 Warnings & Precautions:

• Increased risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection, particularly after long-term use (>2 years), prior immunosuppressants, or exposure to JCV virus

• Requires enrollment in the TOUCH® monitoring program to manage risk and track patients

• Patients should be monitored regularly for new neurological or systemic symptoms during and up to 6 months after treatment

 Storage:

• Store refrigerated between 2–8°C

• Do not freeze; use according to facility guidelines